Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Identification of Significant Prognostic Factors in Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) as Initial Therapy for Chronic Lymphocytic Leukemia

Trial Profile

Prospective Identification of Significant Prognostic Factors in Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) as Initial Therapy for Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 1 Aug 2020 to 1 Aug 2019.
    • 04 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top